COVID-19 Demand Gives Lupin Optimism On Albuterol

Metformin Batch Likely To Be Recalled

Lupin hopes a surge in demand for albuterol sulphate due to increased off-label use in COVID-19 patients will help its generic version, which is likely to be launched in the first half of FY21. But the Indian firm may recall a batch of metformin after the US FDA recently asked a few companies to retract extended-release versions due to NDMA concerns.

Covid19_Lungs_Vial
Off-label Use Of Albuterol For COVID-19 Has Upped Demand • Source: Shutterstock

Lupin expects a shortage of albuterol sulphate in the US, caused by the drug's off-label use in COVID-19 patients, to aid sales of its generic to Teva’s Proair on launch.

But while the Indian company might reap benefits from albuterol, a snowballing of concerns over nitrosamine impurities in metformin, coupled...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Strategy

More from Business